Scientific Updates
Semaglutide Injection NDA for Weight Management Accepted by CDE
Hybio and Sunshine Mandi advance a chemically synthesized semaglutide program toward broader metabolic-health access.
The Center for Drug Evaluation has accepted the New Drug Application for a semaglutide injection intended for long-term weight management.
The submission represents another step in Hybio's strategy to translate peptide process expertise into clinically relevant metabolic-health therapies.
Integrated development
The program brings together chemically synthesized peptide API capabilities, formulation development, quality research, and registration support.
An integrated approach helps align analytical strategy, manufacturing readiness, and regulatory documentation as a program advances.
Focused on metabolic health
Hybio will continue working with its partners to advance the review process and support reliable future supply.
